Measuring the Effects of Complementary Therapies in Chronic Neuropathic Pain
CompletedNot applicableNCT03783624
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The objective of the study is to a) assess the presence of a maladaptive stress response, a decreased pain modulation and any cognitive impairment in patients with chronic neuropathic pain in comparison to healthy controls. and b) evaluate the efficacy of a treatment of hypnosis and of an open label placebo on these neuro-cognitive factors and on clinical pain. This will be done through a) a prospective observational comparative study of patients (base line measures) with Healthy Controls (HC) and b) an Open label; randomised, hypnosis vs. open label placebo (OLP) vs. treatment as usual control design; with a second phase of exploratory cross-over.
Study details
- Official title
- A Randomized-controlled Clinical Trial of Hypnosis Versus Open Label Placebo for Chronic Neuropathic Pain With an Investigation of Neuro-cognitive Dysfunctions as Maintaining Factors and Therapeutic Targets
- Conditions
- Interventions
- Behavioral: Hypnosis
- Behavioral: Open label placebo
- Sponsor
- Chantal Berna
- Organization
- University of Lausanne Hospitals
- Start date
- 2018-11-15
- Primary completion
- 2024-03-15
- Sex
- All
- Age range
- from 18 Years to 90 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- Switzerland
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Patients: Inclusion criteria: * aged 18-90 years, * interested in complementary medicine * peripheral neuropathic pain lasting for more than 6 months, * pain intensity of at least 3/10 VAS over the last two weeks Exclusion criteria: * cognitive deficit (MMSE\<24/30), * severe hearing impairment, * acute psychiatric (e.g. suicidality, psychotic symptoms) or somatic (e.g. unstable cardiorespiratory condition) co-morbidity preventing full engagement in the 8-week study intervention, * prior negative experience with hypnosis, * allergy or intolerance to mannitol. Healthy controls: Inclusion Criteria: * matching patients for age and gender, * no chronic pain condition no acute pain condition requiring daily intake of analgesics, * no acute medical or psychiatric condition.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03783624